Stephen Hodi
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, Melanoma and MAPK Pathways
Most-Cited Works
- → Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors(2019)869 cited
- → Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors(2020)63 cited
- → Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies(2019)43 cited
- → Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy(2019)29 cited
- → Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)(2019)22 cited
- → Risks for Venous Thromboembolism with Immune Checkpoint Inhibitor Therapy(2023)7 cited
- → 7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response(2007)6 cited
- → IT-29 * IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY(2014)4 cited
- → Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity(2015)4 cited